These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients. Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622 [TBL] [Abstract][Full Text] [Related]
13. Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia. Villa M; Lage E; Ballesteros S; Cañas E; Sánchez M; Ordóñez A; Borrego JM; Hinojosa R; Cisneros JM Transplant Proc; 2003 Mar; 35(2):732-4. PubMed ID: 12644115 [No Abstract] [Full Text] [Related]
14. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975 [TBL] [Abstract][Full Text] [Related]
15. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510 [TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus (CMV) DNA amplification from plasma compared with CMV pp65 antigen (ppUL83) detection in leukocytes for early diagnosis of symptomatic CMV infection in kidney transplant patients. Wirgart BZ; Claesson K; Eriksson BM; Brundin M; Tufveson G; Tötterman T; Grillner L Clin Diagn Virol; 1996 Nov; 7(2):99-110. PubMed ID: 9137866 [TBL] [Abstract][Full Text] [Related]
17. The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience. Saracino A; Colucci R; Latorraca A; Muscaridola N; Procida C; Di Noia I; Santospirito VE; Santarsia G Transplant Proc; 2013; 45(1):182-4. PubMed ID: 23375295 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of pp65 antigenemia and viremia in the follow-up of renal transplant recipients with cytomegalovirus disease treated with ganciclovir. Reina J; Ballesteros F; Gasco J; Munar M; Mari M Diagn Microbiol Infect Dis; 2000 Jun; 37(2):83-6. PubMed ID: 10863101 [TBL] [Abstract][Full Text] [Related]
19. Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies. Terlizzi ME; Costa C; Astegiano S; Sidoti F; Vendrame R; Segoloni GP; Bergallo M; Cavallo R Minerva Med; 2008 Jun; 99(3):231-9. PubMed ID: 18497721 [TBL] [Abstract][Full Text] [Related]
20. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]